Medicis Pharmaceutical’s subsidiary Medicis Technologies has received US Food and Drug Administration (FDA) clearance for its second generation LipoSonix system, designed for non-invasive waist circumference reduction.

The LipoSonix system uses high-intensity focused ultrasound energy to disrupt subcutaneous adipose tissue.

The approval is backed by a multicentre, randomised, sham-controlled and blind study, which showed that treatment with the LipoSonix system was superior to a sham control in reducing waist circumference.

Clinical studies conducted by Medicis Technologies demonstrated an average waist circumference reduction of approximately 2.6cm after a single treatment with the LipoSonix system.

The first generation LipoSonix system is currently available in Canada, the European Union and Japan.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.